

LIPIGON DEVELOPS FIRST- OR BEST-IN-CLASS TREATMENTS FOR ORPHAN INDICATIONS IN THE LIPID RELATED DISEASE AREA.



Market need and potential

Homozygote FH (HoFH) is an orphan indication that has a prevalence of 1 in 160,000. This rare genetic disorder is strongly associated with CVD and premature death; untreated, it often causes heart disease in the early teen years. HoFH patients are largely unresponsive to conventional treatments. This is because these drugs are dependent on a specific receptor mechanism that is mutated in most FH patients (LDL receptor). Hence, there is a significant urgent demand on novel treatments that utilize a different mechanism of action. Sales predictions for HoFH drugs by 2023 are \$600 M.

Business idea

What distinguishes Lipigon to its competitors is the combination of lipid biology expertise combined with the advanced ASO platform. Lipisense is hitting two important targets at once is anticipated to target an LDLr independent mechanism lowering LDL in HoFH patients together with improving other important lipid moieties. This strategy is unmatched by current competitors. Furthermore, the effects on LDL-cholesterol are expected upon a single injection, which is a very attractive clinical development feature unique to Lipisense. Developing orphan therapies has a number of advantages, including less extensive clinical trials, support from authorities, advice and opportunities for market exclusivity in the EU (10 years) and the US (7 years), reduced fees for regulatory activities.

Competition

	Novelty: Mechanism of action	Efficacy: Suitable for all FH patients	Cost (EUR)	Ease of use: Route of administration
Statins	LDLr dependent	No	100	Oral
PCSK9 inhibitors	LDLr dependent	No	5-15K	Injection
Lomitapide	Non-LDLr dependent	Yes (but leads to liver lipid retention)	245K	Oral
Mipomersen	Non-LDLr dependent	Yes (but leads to liver lipid retention)	245K	Injection
Lipisense	Non-LDLr dependent	Yes	250K	Injection

Photos by Johan Günséus

Lipigon's pipeline

Treatment	Preclinical			Clinical development			Approval	Partner
	Identification	Optimization	Safety	Phase 1	Phase 2	Phase 3		
Familial Hypercholesterolemia			2019	2020				Secarna
Lipodystrophy			2020					Ongoing
CVD/dyslipidemia			2019-2020					Ongoing

COMPANY PROFILE

Contact

Stefan K Nilsson
Phone: +46 70 578 1768
E-mail: stefan@lipigon.se

Website

www.lipigon.se

IPR

ASO based treatment for HoFH filed November 2018

Capital need

20 MSEK pre-IPO Q2 2019 to cover pre-clinical safety/tox

50 MSEK IPO Q2 2020 to cover first-in-man Phase 1 trials

Partnership

We are seeking contact with private and institutional investors, VC companies and pharmaceutical partners with an interest in metabolic disease

Management / Board

Carina Schmidt
Chairperson – life science professional

Lars Öhman
Board – business development

Erik Lund
PhD, Board – business development

Mikael Elofsson
Prof. Board – medicinal chemist

Team

Stefan K Nilsson
PhD, MBA, CEO - entrepreneur

Gunilla Olivecrona
Prof. CSO – molecular lipid transport expert

Background

Lipigon was founded 2010 by Lipid biology experts. The company aims at building a sustainable research-based company with a rich pipeline of product candidates to bring major inflection points alone or in collaboration with partners.